Âé¶¹´«Ã½

    Advertisement
    Futurism15:03Eli Lilly Ozempic Pharma
    Scientific American08:49Eli Lilly Ozempic Pharma
    Fox News17:55Ozempic FDA Pharma
    The Motley Fool08:47Ozempic FDA Pharma
    The Motley Fool05:50Pharma
    The Motley Fool12:20Pharma
    Business Plus Online04:18Ozempic Pharma Business (US)
    This is Money17:17Ozempic Pharma Business (US)
    The Motley Fool04:38Ozempic Eli Lilly Tirzepatide
    Benzinga15:36Mounjaro Ozempic Eli Lilly
    Benzinga16:31Mounjaro Ozempic Eli Lilly
    Gulf Times17:28Eli Lilly India Pharma
    The Economic Times20:45Eli Lilly India Pharma
    Zacks18:53Pharma Nasdaq Markets
    Zacks10:05Pharma Nasdaq Markets
    Campaign Brief23:41Obesity Australia Pharma
    B&T Marketing & Media19:48Obesity Australia Pharma
    Yahoo! UK & Ireland06:11Jerome Powell Tesla, Inc. Federal Reserve
    Earlier today
    Business Wire (Press Release)10:27
    The Times of India06:33
    The Motley Fool05:50
    The Motley Fool05:09
    Business Plus Online04:18
    GlobeNewswire (Press Release)03:01
    Yesterday
    This is Money17:17 22-Apr-25
    The Times of India15:05 22-Apr-25
    The Motley Fool12:20 22-Apr-25
    Gizmodo12:14 22-Apr-25
    The Hindu Business Line11:52 22-Apr-25
    Macau Business10:43 22-Apr-25
    FiercePharma09:03 22-Apr-25
    Sifted08:57 22-Apr-25
    The Motley Fool08:47 22-Apr-25
    Yahoo! UK & Ireland06:11 22-Apr-25
    Fortune05:14 22-Apr-25
    The Economic Times04:12 22-Apr-25
    Invezz02:53 22-Apr-25
    The Times of India02:34 22-Apr-25
    Motley Fool (UK)01:39 22-Apr-25
    In the last 7 days
    Zacks18:53 21-Apr-25
    Scrip Pharma Intelligence15:47 21-Apr-25
    Green Queen11:35 21-Apr-25
    Zacks10:05 21-Apr-25
    The Motley Fool09:23 21-Apr-25
    Scientific American08:49 21-Apr-25
    The Motley Fool04:38 21-Apr-25
    Gulf Times17:28 20-Apr-25
    TipRanks10:04 19-Apr-25
    The Motley Fool03:28 19-Apr-25
    The Economic Times20:11 18-Apr-25
    Nasdaq16:11 18-Apr-25
    Futurism15:03 18-Apr-25
    Pharmacy Times13:35 18-Apr-25
    Power Corridor06:32 18-Apr-25
    The Irish Times04:23 18-Apr-25
    Benzinga22:30 17-Apr-25
    Law36022:16 17-Apr-25
    Hindustan Times21:26 17-Apr-25
    FiercePharma16:39 17-Apr-25
    Benzinga15:36 17-Apr-25
    Yahoo! US14:50 17-Apr-25
    The Motley Fool12:47 17-Apr-25
    Forbes10:53 17-Apr-25
    Yahoo! UK & Ireland10:33 17-Apr-25
    London South East08:48 17-Apr-25
    NBC Connecticut08:13 17-Apr-25
    Korea Biomedical Review01:03 17-Apr-25
    Fox News17:55 16-Apr-25
    NPR16:07 16-Apr-25
    Vice (US)15:02 16-Apr-25
    Pharmaceutical Technology11:18 16-Apr-25
    The Kansas City Star01:00 16-Apr-25
    In the last month
    KCBD, Texas23:23 15-Apr-25
    KCRG TV 9, Iowa22:26 15-Apr-25
    Law36021:04 15-Apr-25
    ABC7 / WLS-TV21:02 15-Apr-25
    PR Newswire (Press Release)17:22 15-Apr-25
    Benzinga16:31 15-Apr-25
    Black Enterprise16:03 15-Apr-25
    Benzinga15:20 15-Apr-25
    Zacks11:03 15-Apr-25
    The Motley Fool10:23 15-Apr-25
    Business Wire (Press Release)09:01 15-Apr-25
    Business Wire (Press Release)05:34 15-Apr-25
    Northwest Arkansas Democrat-Gazette03:36 15-Apr-25
    Bernama02:02 15-Apr-25
    Campaign Brief23:41 14-Apr-25
    WHDH-TV, Massachusetts22:09 14-Apr-25
    NBC Connecticut20:38 14-Apr-25
    B&T Marketing & Media19:48 14-Apr-25
    Law36019:26 14-Apr-25
    UPI18:47 14-Apr-25
    Bloomberg Law12:59 14-Apr-25
    Science|Business12:28 14-Apr-25
    Investing.com UK11:50 14-Apr-25
    PR Newswire (Press Release)11:49 14-Apr-25
    The Motley Fool11:18 14-Apr-25
    PR Newswire (Press Release)10:59 14-Apr-25
    Yahoo! US10:52 14-Apr-25
    The Economic Times10:19 14-Apr-25
    AdNews10:09 14-Apr-25
    Gulf News09:04 14-Apr-25
    pharmaphorum08:19 14-Apr-25
    Motley Fool (UK)02:33 13-Apr-25
    The Economic Times20:45 11-Apr-25
    Scrip Pharma Intelligence11:07 11-Apr-25
    Zacks10:44 11-Apr-25
    Korea Biomedical Review05:03 11-Apr-25
    Law36021:47 10-Apr-25
    FoodNavigator.com12:04 10-Apr-25
    Science News Online11:03 10-Apr-25
    Zacks06:03 10-Apr-25
    Yahoo! UK & Ireland05:58 10-Apr-25
    Zacks18:01 9-Apr-25
    Pharmaceutical Online14:07 9-Apr-25
    The Motley Fool10:03 9-Apr-25
    Pharmaceutical Technology08:00 9-Apr-25
    ENDPOINTS06:56 9-Apr-25
    Morningstar06:44 9-Apr-25
    Fortune06:41 9-Apr-25
    Law36020:26 8-Apr-25
    MorningStar.com19:34 8-Apr-25
    Bloomberg Law19:08 8-Apr-25
    Courthouse News14:15 8-Apr-25
    The Economic Times12:46 8-Apr-25
    Global Construction Review12:31 8-Apr-25
    ENDPOINTS11:37 8-Apr-25
    Zacks11:18 8-Apr-25
    Zacks10:07 8-Apr-25
    FiercePharma09:57 8-Apr-25
    Radio Tamazuj05:29 8-Apr-25
    World Food Programme (Press Release)04:07 8-Apr-25
    BioWorld17:02 7-Apr-25
    view more headlines
    23 Apr 10:27

    About our Novo Nordisk news

    Latest news on Novo Nordisk, a global healthcare company focused on diabetes care, obesity treatment, and other serious chronic diseases. Get updates on Novo Nordisk's products, research, financial performance, and stock price.

    Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. Founded in 1923, the company has grown to become a global leader in diabetes care, with a strong presence in the fields of hemophilia, growth hormone therapy, and obesity treatment. Novo Nordisk's key products include insulin analogs like Tresiba and Levemir, GLP-1 receptor agonists such as Victoza and Ozempic, and obesity drugs like Saxenda and Wegovy.

    Stay informed about the latest developments in Novo Nordisk's research and development pipeline, including updates on clinical trials, regulatory approvals, and new product launches. Our feed covers the company's ongoing efforts to innovate and improve treatments for diabetes, obesity, and other metabolic disorders, such as the development of oral semaglutide and the exploration of novel drug targets.

    In addition to product news, our Novo Nordisk feed keeps you updated on the company's financial performance, including quarterly earnings reports, sales figures, and market share data. We also cover key events and announcements that may impact Novo Nordisk's stock price (NYSE: NVO), such as strategic partnerships, acquisitions, and leadership changes.

    Beyond the business aspects, our feed highlights Novo Nordisk's commitment to corporate social responsibility and sustainability. From initiatives to improve access to diabetes care in developing countries to efforts to reduce the company's environmental footprint, we provide a comprehensive view of Novo Nordisk's impact on global health and society.

    As the prevalence of diabetes and obesity continues to rise worldwide, Novo Nordisk plays a crucial role in addressing these global health challenges. Our Âé¶¹´«Ã½ feed on Novo Nordisk brings you the most relevant and up-to-date information from reliable sources, helping you stay informed about this innovative and influential healthcare company.


    Publication filters

    Headline Density

    Sorry, no headlines or news topics were found. Please try different keywords.